Leidi.com Lei Jianping July 17
Beijing Zhaoyan New Drug Research Center Co., Ltd. (abbreviation: "Zhaoyan New Drug") recently released a performance forecast. It is estimated that the revenue from January to June 2023 will be about 973 million to 1.05 billion yuan. Compared with the data of the same period last year, It will increase by about 196 million yuan to 274 million yuan, a year-on-year increase of about 25.3% to 35.3%.
Zhaoyan New Drug expects to realize a net profit attributable to shareholders of listed companies of about 72.7657 million yuan to 110 million yuan from January to June 2023, which will decrease by about 261 million yuan to 298 million yuan compared with the data in the same period of the previous year, a year-on-year decrease. About 70.4% to 80.4%.
Zhaoyan New Drug expects to realize the net profit attributable to shareholders of listed companies after deduction of non-recurring gains and losses from January to June 2023 of about 60.3249 million to 94.837 million yuan, which will decrease by about 250 million yuan to 285 million yuan compared with the data for the same period last year. billion, a year-on-year decrease of approximately 72.5% to 82.5%.
Among them: the net profit of the laboratory service business is about 189 million to 204 million yuan, which will increase by about 39.291 million to 54.222 million yuan compared with the data in the same period of the previous year, an increase of about 26.3% to 36.3% year-on-year.
Mainly affected by factors such as government subsidies and income from transactional financial assets, the amount of impact on net profit after deducting income tax from non-recurring gains and losses was about 14 million, a decrease of about 12 million compared with the same period last year.
Affected by the poor performance, the stock price of Zhaoyan New Pharmaceutical's A shares fell by the limit. As of now, the company's share price is 36.86 yuan, with a market value of 19.744 billion yuan.
Zhou Zhiwen, one of the actual controllers, cashed out 550 million
Zhou Zhiwen, one of the actual controllers of Zhaoyan New Drug, reduced his holdings through centralized bidding transactions and block transactions from January 3 to June 21, 2023. The reduction ratio was 2.05% of Zhaoyan New Drug’s equity.
Zhou Zhiwen reduced the number of shares this time to 10,997,810 shares, the average price of the reduction was 41.7 yuan to 68.34 yuan, and the total amount of the reduction was 551 million yuan.
Before this shareholding reduction, Feng Yuxia held 22.29% of the shares, and Zhou Zhiwen held 12.02% of the shares. The two are married and hold a total of 34.31% of the shares. After this shareholding reduction, Zhou Zhiwen held 9.96% of the shares.
In April 2023, Zuo Conglin, Yao Dalin, Sun Yunxia, Gao Dapeng, directors of Zhaoyan New Pharmaceutical, Li Ye, supervisor, Yu Aishui, Gu Jingliang, and Xu Jie, who acted in concert, also proposed a shareholding reduction plan. Gu Jingliang and Xu Jie are husband and wife.
The above-mentioned 8 persons hold 13,871,669 shares, 72,470 shares, 2,563,419 shares, 274,104 shares, 73,201 shares, 24,360 shares, 192,715 shares and 3,293 shares of the company respectively, and the shareholding ratios are 2.59%, 0.014%, 0.48%, 0.05%, 0.014% respectively %, 0.005%, 0.036% and 0.0006%.
Zuo Conglin, Yao Dalin, Sun Yunxia, Gao Dapeng, Li Ye, Yu Aishui, Gu Jingliang, and Xu Jie plan to start six months after 15 trading days from the date of announcement of this shareholding reduction plan (i.e. starting from May 17). During the period, through block trading or centralized bidding on the Shanghai Stock Exchange, the reduction of holdings did not exceed 3,467,000 shares, 18,000 shares, 640,000 shares, 68,000 shares, 18,000 shares, 6,000 shares, 48,000 shares, and 3,293 shares, and the total reduction of holdings did not exceed 4,268,293 shares , not exceeding 0.8% of the company's current total share capital.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
